Satyadivis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 7.65 M
as on 26-07-2024
- Company Age 32 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 18.55 Cr
as on 26-07-2024
- Revenue 3.26%
(FY 2023)
- Profit -5.53%
(FY 2023)
- Ebitda -10.90%
(FY 2023)
- Net Worth 20.32%
(FY 2023)
- Total Assets 17.47%
(FY 2023)
About Satyadivis Pharmaceuticals
The Corporate was formerly known as Divis Pharmaceuticals Pvt.Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.65 M.
The company has closed loans amounting to ₹18.55 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Divi Rao and Divi Mohan serve as directors at the Company.
- CIN/LLPIN
U24239TG1992PTC014939
- Company No.
014939
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Oct 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Jinnaram, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Satyadivis Pharmaceuticals Private Limited offer?
Satyadivis Pharmaceuticals Private Limited offers a wide range of products and services, including Chemical Compound, Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, Pharmaceutical Capsules, Fluoxetine Capsule.
Who are the key members and board of directors at Satyadivis Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Divi Mohan  | Managing Director | 27-Oct-1992 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Divi Rao | Director | 27-Oct-1992 | Current |
Financial Performance and Corporate Structure Insights of Satyadivis Pharmaceuticals.
Satyadivis Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.26% increase. The company also saw a slight decrease in profitability, with a 5.53% decrease in profit. The company's net worth Soared by an impressive increase of 20.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satyadivis Pharmaceuticals?
In 2023, Satyadivis Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 23 Jun 1998 | ₹18.00 Cr | Satisfied |
Andhra Pradesh State Financial Corporation Creation Date: 08 Feb 1994 | ₹5.53 M | Satisfied |
How Many Employees Work at Satyadivis Pharmaceuticals?
Satyadivis Pharmaceuticals has a workforce of 64 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satyadivis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satyadivis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
